Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer

被引：0
|
作者：
Tarantino, Paolo
Lee, Do
Foldi, Julia
Soulos, Pamela R.
Gross, Cary Philip
Grinda, Thomas
Winer, Eric P.
Lin, Nancy U.
Krop, Ian E.
Tolaney, Sara M.
Lustberg, Maryam B.
Sammons, Sarah L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Yale Sch Med, New Haven, CT USA
[3] UPMC, Pittsburgh, PA USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1077
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment and outcomes of older versus younger women with HER2 positive metastatic breast cancer in the real-world national ESME database
    Annonay, Mylene
    Gauquelin, Lisa
    Geiss, Romain
    Ung, Mony
    Cristol-Dalstein, Laurence
    Mouret-Reynier, Marie-Ange
    Goncalves, Anthony
    Abadie-Lacourtoisie, Sophie
    Francois, Eric
    Perrin, Christophe
    Le Fel, Johan
    Lorgis, Veronique
    Servent, Veronique
    Uwer, Lionel
    Jouannaud, Christelle
    Leheurteur, Marianne
    Joly, Florence
    Campion, Loic
    Courtinard, Coralie
    Villacroux, Olivier
    Petit, Thierry
    Soubeyran, Pierre
    Terret, Catherine
    Bellera, Carine
    Brain, Etienne
    Delaloge, Suzette
    BREAST, 2021, 60 : 138 - 146
  • [42] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [43] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
    Lin, N.
    Ciruelos, E. M.
    Jerusalem, G.
    Mueller, V.
    Niikura, N.
    Viale, G.
    Bartsch, R.
    Kurzeder, C.
    Connolly, R.
    Baron-Hay, S. E.
    Cortes, M. Gion
    Guarneri, V.
    Bianchini, G.
    Wildiers, H.
    Escriva-de-Romani, S.
    Prahladan, M.
    Bridge, H.
    Verma, S.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
  • [44] Real World Data for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
    Toler, Andrew
    Bobolts, Laura R.
    Mangurian, Mark
    Pozotrigo, Melissa
    Wise, Corey
    Solomon, Hiywete
    Hartung, Nicole
    Makielski, Rory
    Marur, Shika
    Ravindranathan, Meera
    Marur, Shanthi
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Desplas, David
    Mansouri, Imene
    Zureik, Mahmoud
    Di Meglio, Antonio
    Haddy, Nadia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 531
  • [46] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [47] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).
    Alder, Laura
    Trapani, Dario
    Van Swearingen, Amanda
    Khasraw, Mustafa
    Anders, Carey
    Lin, Nancy
    Sammons, Sarah
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK
    Cheng, Andy
    Frank, Suzanne
    Baines, Katherine
    Nathan, Mark
    Douglas, Rosalie V.
    Sylva, Rushan
    Ball, Jessica
    Savva, Constantinos
    Talbot, Thomas
    Oikonomidou, Olga
    Smith, Jenny
    Thomson, Alastair
    Ross, Felicity
    Konstantis, Apostolos
    Ainsworth, Nicola
    Luciano, Pietro
    Iyer, Pooja
    Acharige, Shyamika
    Rana, Shaikh
    King, Judy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Interstitial Lung Disease Associated with Trastuzumab Deruxtecan in HER2D Metastatic Breast Cancer: a Real-world Experience
    Shaheen, A.
    Hayhurst, H.
    Omokhodion, O.
    Ayyad, A.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E111 - E112
  • [50] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205
12345